Innoviva Inc. (INVA)
Market Closed
16 Oct, 08:00 PM
$
20. 78
-0.08
-0.3835%
Pre Market
$
-0.01 -0.0481% 20. 77
1.5B Market Cap
6.58 P/E Ratio
- Div Yield
550,482 Volume
0.81 Eps
$ 20.86
Previous Close 
Want to track INVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The company is transitioning from a royalty collector to an operator in specialty therapeutics, with significant growth in product sales, notably GIAPREZA and XACDURO. Key assets like Zevtera, an advanced-generation antibiotic, and a promising pipeline in infectious diseases, position Innoviva for potential market disruption and growth.
Seekingalpha | 1 year ago
2026 © Marketlog. All Rights Reserved.
